The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.
The investment bank previously had a Neutral rating for the company, and it lowered the price target on Genomic Health's stock to $25 from $28.
The investment bank said NeoGenomics and its clients are likely to benefit from a product portfolio expanded by the acquisition of Clarient.
There were more winners than losers in the 2015 GWDN Index, but some lost big.
The bank downgraded Quidel's shares to market perform and trimmed its Q4 revenue forecast due to a mild flu season.
The investment firm has added the three companies to its US Life Science Tools & Diagnostics coverage while upping Hologic to an Equal Weight rating.
Mizuho and William Blair downgraded Bruker, following the resignation of CFO Charles Wagner, who was noted for his role in implementing a turnaround at the company.
NEW YORK (GenomeWeb) – Investment bank Piper Jaffray on Thursday initiated coverage of Veracyte with an overweight rating on the firm's stock and a $21 price target.
NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray has initiated coverage of PerkinElmer with an Overweight rating and a $46 price target.
NEW YORK (GenomeWeb News) – Following a spike in Life Technologies' share price after a report that the company may be searching for a buyer, investment firm William Blair today downgra
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.